SCHEMBL3244796

SCHEMBL3244796

Cc1cccc(C(=O)NC(c2ccccc2)C(C)(C)N2CCCC2C)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
TAS1R2 Q8TE23 1/20 0.44
SLC6A9 P48067 7/20 0.44
ALDH1A1 P00352 1/20 0.39
CCR1 P32246 1/20 0.39
P2RX7 Q99572 2/20 0.38
ACE P12821 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD11B1 P28845 1/20 0.37
ITGB3 P05106 2/20 0.37
ITGA2B P08514 2/20 0.37
POLB P06746 1/20 0.36
MGLL Q99685 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3232882 0.89 SLC6A9 (0.45) SLC6A9ALDH1A1P2RX7MAPT
SCHEMBL3244195 0.88 SLC6A9 (0.59) SLC6A9P2RX7
SCHEMBL3240097 0.87 SLC6A9 (0.46) SLC6A9ALDH1A1LMNASMN1; SMN2
SCHEMBL3236750 0.84 ALDH1A1 (0.39) SLC6A9ALDH1A1LMNAHTTKMT2A
SCHEMBL3238470 0.83 SLC6A9 (0.46) TAS1R3TAS1R1TAS1R2SLC6A9ALDH1A1
SCHEMBL3237083 0.83 POLB (0.42) ALDH1A1LMNASMN1; SMN2ITGB3ITGA2B
SCHEMBL3242223 0.83 NPC1 (0.40) TAS1R3TAS1R1TAS1R2ALDH1A1LMNA
SCHEMBL3238447 0.82 SLC6A9 (0.40) SLC6A9ALDH1A1LMNA
SCHEMBL3245182 0.82 HPGD (0.45) ALDH1A1LMNAMAPTHTTKMT2A
SCHEMBL3232907 0.81 ALDH1A1 (0.39) TAS1R3TAS1R1TAS1R2SLC6A9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 TAS1R3 3167/4885TAS1R1 2565/4885TAS1R2 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.